On April 28, 2025, Iterum Therapeutics plc finalized a deal to raise approximately $5 million by issuing 3,040,000 ordinary shares and pre-funded warrants, expecting net proceeds of about $4.2 million to support operations and pre-commercialization activities until 2026.